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AbsTrACT
Objective To study the effect of botulinum neurotoxin 
(BoNT) treatment in jerky and tremulous functional 
movement disorders (FMD).
Methods patients with invalidating, chronic (>1 year) 
symptoms were randomly assigned to two subsequent 
treatments with BoNT or placebo every 3 months 
with stratification according to symptom localisation. 
Improvement on the dichotomised clinical Global 
Impression-Improvement scale (cGI-I) (improvement 
vs no change or worsening) at 4 months, assessed by 
investigators blinded to the allocated treatment was the 
primary outcome. subsequently all patients were treated 
with BoNT in a ten month open-label phase.
results Between January 2011 and February 2015 
a total of 239 patients were screened for eligibility of 
whom 48 patients were included. No difference was 
found on the primary outcome (BoNT 16 of 25 (64.0%) 
vs placebo 13 of 23 patients (56.5%); proportional 
difference 0.075 (95% cI −0.189 to 0.327; p=0.77). 
secondary outcomes (symptom severity, disease burden, 
disability, quality of life and psychiatric symptoms) 
showed no between-group differences. The open-label 
phase showed improvement on the cGI-I in 19/43 
(44.2%) of remaining patients, with a total of 35/43 
(81.4%) improvement compared with baseline.
Conclusions In this double-blind randomised controlled 
trial of BoNT for chronic jerky and tremulous FMD, we 
found no evidence of improved outcomes compared with 
placebo. Motor symptoms improved in a large proportion 
in both groups which was sustained in the open-label 
phase. This study underlines the substantial potential of 
chronic jerky and tremulous FMD patients to recover and 
may stimulate further exploration of placebo-therapies in 
these patients.
Trial registration number NTR2478
InTrOduCTIOn
Despite the fact that functional neurological symp-
toms (FNS) comprise a third of the patient popu-
lation of a neurologist, and disease and financial 
burden on the healthcare system is large, research 
on optimal treatment in this field has been very 
limited. In movement disorder clinics functional 
movement disorders (FMD) account for up to 25% 
of patients seen.1 2 The diagnosis is based on posi-
tive clinical symptoms, supported by neurophysio-
logical tests.2–4 Among FMD, jerks and tremor are 
frequently seen and have a relatively poor outcome 
at long-term follow-up (3–7 years).5 6 Botulinum 
neurotoxin (BoNT) has emerged as a useful therapy 
for several movement disorders associated with 
muscle overactivity, including dystonia, and tics.7 8 
The mechanism of action of BoNT is more exten-
sive than blocking muscle activity alone; in dystonia 
for instance there is supporting evidence that BoNT 
induces plastic changes in the brain.9 Case reports 
in FMD have reported promising effects of BoNT 
treatment,6 10 especially in functional dystonia 
in which large placebo-effects have also been 
described.11 This has stressed the importance of 
conducting a controlled clinical trial to disentangle 
response to an active agent vs placebo. Based on the 
literature, and our own experience in patients with 
jerky and tremulous FMD, we hypothesised that 
BoNT treatment enables restoring the abnormal 
movement pattern and therefore will be more effec-
tive than placebo. To study the long-term effects of 
BoNT, a subsequent open-label extension study was 
conducted following the randomised trial phase.
MeThOds
study design
This study was designed as a 4-month single-centre, 
randomised, double-blind, placebo-controlled trial 
(RCT), followed by an open-label extension phase 
consisting of up to four treatment sessions for an 
additional period up to 10 months. BoNT injec-
tions were compared with injections with placebo 
in patients with jerky and tremulous FMD. In the 
follow-up period, the long-term effects of BoNT 
injections were assessed.
This study was performed at a tertiary referral 
centre for movement disorders in the Amsterdam 
UMC, the Netherlands.
Patients
All eligible patients with jerky and tremulous 
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clinic from 2000 or specifically referred to us for this study. 
Included patients had incapacitating functional jerks for at least 
1 year, were aged between 18 and 80 years. To improve inclu-
sion, during the study an amendment of the protocol was made 
adding patients with functional tremor. The diagnosis was made 
by two experienced movement disorder specialists (JHTMK, 
MAJT) and symptoms had to fulfil the criteria for ‘definite’ or 
‘probable’ FMD.2 No change in medication was allowed in the 
month prior to participation. Exclusion criteria were pregnancy, 
coagulation disorders and insufficient knowledge of the Dutch 
language.
randomisation and masking
An independent trial nurse, not involved in the treatment or 
assessment of the outcome measures, carried out a web-based 
randomisation procedure (ALEA; www. aleaclinical. eu) and 
prepared the study medication. BoNT is available as powder 
for injection; after dissolving it is a colourless fluid indistin-
guishable from sterile saline which was used as placebo. Both 
BoNT and placebo were prepared in identical syringes. Patients 
were randomised with a ratio of 1:1 to BoNT or placebo treat-
ment. Randomisation was stratified by localisation of symptoms 
(extremity vs axial), using permuted blocks with varying block 
sizes (2 and 4). All patients were treated by the same experi-
enced neurophysiologist (JHTMK). The patients, treating physi-
cians and research group were uninformed about the allocated 
treatment.
Procedures
Treatment consisted of either intramuscular injections with 
BoNT type A (BoNT-A) or placebo. Freeze-dried BoNT-A 
(Dysport, Ipsen BV, Hoofddorp, the Netherlands) was diluted 
to 20 units (IU) per 0.1 mL of 0.9% sterile saline and aspirated 
in 1 mL syringes. Placebo consisted of an equivalent volume of 
0.9% sterile saline. Injections were given under simultaneous 
electromyogram recordings into selected muscles using a hollow, 
Teflon-coated, 27-gauge needle.
During the RCT, all patients were treated twice with either 
BoNT or placebo; at baseline and 3 months thereafter. The 
dosages of BoNT were based on the volume of the muscle(s) 
injected.12 Similar to an RCT in writer’s cramp, the dosage was 
doubled at the second treatment according to the degree of 
response.13 After 3 months, all patients subsequently received 
treatment with BoNT in an open-label extension phase, resulting 
in a maximum of 4 open-label injections.
At baseline, patients underwent a standardised neurological 
examination, video recording with a standardised protocol 
(online appendix 4), and demographic characteristics were gath-
ered. Explanation of the study including efficacy and the most 
common adverse events of BoNT were given (online appendix 
2). All patients underwent electrophysiological examination 
(polymyography) to support FMD and to select muscles for 
BoNT treatment.3 In suitable patients, an electroencephalog-
raphy was added to support FMD (eg, bereitschaftspotential).14
Outcomes
The outcome measures were assessed at baseline, at 4 months 
(primary endpoint) and 4 weeks after the last treatment (end 
of study). Outcome indicators were: motor symptoms, motor 
severity, disease burden, muscle weakness, disability, quality 
of life and quantitative psychiatric assessment. The primary 
endpoint was improvement of motor symptoms based on the 
video recordings rated by investigators using the Clinical 
Global Impression–Improvement (CGI-I) scale (a 7-point scale, 
ranging from 1=very much improved to 7=very much worse).15 
Improvement was defined as a CGI-I score 1, 2 or 3.
The severity of motor symptoms was determined using the 
Clinical Global Impression–Severity (CGI-S) Scale (a 7-point 
scale, 1=no symptoms to 7=very severe symptoms) and the 
Psychogenic Movement Disorder Rating Scale (PMDRS).16 Two 
investigators (out of nine assessors: JD, JG, EZ, DP, MFC, RZ, 
BP, AM, JDS) per subset of patients who were blinded to the 
allocated treatment independently assessed symptom improve-
ment (CGI-I) and severity (CGI-S, PMDRS) based on the video 
recordings. Ratings of the most experienced rater were used in 
the final analysis. The second rater served in an inter-observer 
analysis.
Patients rated their perceived symptom improvement and 
severity using the CGI-I and CGI-S as well, combined with a 100 
mm horizontal Visual Analogue Scale measuring disease burden 
(0 indicating no disease burden and 100 indicating the worst 
possible disease burden). Muscle weakness and atrophy were 
examined objectively by a blinded physician (JHTMK) using the 
Medical Research Council (MRC) scale. The Academic Medical 
Center (AMC) Linear Disability Score was used to measure activ-
ities of daily life. Quality of life was assessed using the 36-item 
Short Form Health Survey (SF-36). Quantitative questionnaires 
concerning psychiatric symptoms were assessed, including the 
Beck Depression Inventory, Montgomery Asberg Depression 
Rating Scale, Beck Anxiety Inventory, Liebowitz Social Anxiety 
Scale, Obsessive Compulsive Inventory (online appendix 1).
The most common adverse events of BoNT (pain, weakness, 
influenza-like symptoms and any other negative effects) were 
actively asked for. During the trial phase, patients were asked 
whether they thought they received BoNT or placebo, how 
much confidence they had in the treatment beforehand and 
whether they wanted to continue treatment.
Statistical analysis
We assumed that 30% of patients in the placebo group and 70% 
of the patients of the BoNT group would reach the primary 
endpoint. The placebo effect was hypothesised to be larger than 
the effect size found in a similar BoNT trial in focal dystonia 
(writer’s cramp).13 A two-group Χ2 test with a 0.05 two-sided 
significance level generated a sample size of 24 patients per arm 
with a power of 80%.
All analyses were done according to the intention-to-treat 
principle. The baseline characteristics, outcome parameters 
and (serious) adverse events were summarised using descriptive 
statistics. The CGI-I was dichotomised to improvement (score 
1,2 or 3) vs no change or worsening (score 4,5,6,7). Between-
group differences in proportions (trial phase) were assessed using 
the χ2 test or Fisher’s exact test, when appropriate. Statistical 
uncertainty was expressed in a two-sided 95% CI. With regard 
to the primary outcome indicator, we additionally performed 
multivariable logistic regression with treatment groups and the 
stratification factor (axial vs extremity) as independent variables. 
The effect size was expressed in an adjusted OR.
As most continuous secondary outcome measures were 
non-normally distributed, all outcome measures were described 
in median scores, with their IQR).
The within-group median change scores (from baseline to 
outcome assessment) in the trial phase were calculated as the 
50th percentile of all individual differences. Point estimate and 
95% CI of the median differences in change scores between 
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Figure 1 study flow chart: enrolment, randomisation and follow-up of 
patients. For details on reasons why patients did not fulfil the inclusion 
criteria, see online appendix 2. BoNT, botulinum neurotoxin.
approach.17 Between-group difference in change scores was also 
analysed using the Mann-Whitney U test.
The difference in within-group median scores in the open-
label extension phase was analysed with the Wilcoxon signed-
rank test for paired data.
Interobserver agreements of the ordinal ratings on the CGI-I 
and CGI-S were analysed using the average weighted Kappa 
(K) statistic. With regard to the interobserver agreements of 
the continuous PMDRS scores, we used the average intraclass 
correlation coefficient (ICC) (online appendix 2).
A two-sided p value <0.05 was considered statistically signifi-
cant. Missing data were not imputed and no interim analysis was 
performed. All analyses were performed in IBM SPSS Statistics 
V.24 and STATA V.15. The pre-defined statistical analysis plan is 
available in online appendix 3.
Post-hoc analyses
The primary outcome measure was analysed setting a higher bar 
of improvement (CGI-I score 1–2 vs 3–7). Possible predictors of 
treatment outcome on the CGI-I were analysed using a logistic 
regression including: symptom duration, psychiatric co-mor-
bidity (anxiety/depressive disorder), quantitative pain measures 
(subscale SF-36), pain disorder, confidence in treatment before-
hand and which treatment arm patients thought they were in.
Classification of evidence
The aim of this was to provide class I evidence according to 
the classification of evidence from the American Academy of 
Neurology18 19 on the effect of BoNT treatment in patients with 
jerk-like FMD.
sTAndArd PrOTOCOl APPrOvAls, regIsTrATIOns And 
PATIenT COnsenTs
The trial is registered in the Dutch Trial Register (NTR 2478) 
(http://www. trialregister. nl/ trialreg/ admin/ rctview. asp? TC= 
2478) and was monitored by an independent monitor of the 
Amsterdam University Medical Center (UMC), according to 
Good Clinical Practice (GCP) guidelines. The study protocol can 
be found online (https://www. amc. nl/ web/ specialismen/ neurol-
ogie- 1/ botulinum- neurotoxin- bont- trial. htm).
resulTs
Between 27 January 2011 and 18 February 2015 a total of 
239 patients were screened for eligibility of whom 49 patients 
were randomised and 48 actually received treatment (figure 1). 
For details on reasons of exclusion see online supplementary 
appendix 2. Twenty-five patients were treated with BoNT and 
23 patients with placebo. All patients were BoNT-naïve except 
for one patient who was treated ineffectively once before. He 
was considered to possibly benefit from treatment with better 
muscle selection using polymyography. All patients completed 
the trial phase of the study. The baseline characteristics are 
summarised in table 1. The majority of patients in both treat-
ment arms underwent previous other sorts of treatments. Exam-
ples of included patients reflecting the clinical spectrum are 
shown in online videos 1-3.
Trial phase
Due to pain/worsening symptoms (n=2) and complete resolu-
tion of symptoms (n=1), 3 patients discontinued BoNT treat-
ment after one injection. One patient discontinued the study 
after two BoNT injections because of pain (figure 1). In one 
patient, assessment of the primary endpoint was delayed to 1 
year instead of 4 months due to personal circumstances.
In the BoNT arm the median initial dose was 240 IU (IQR 
140–400) followed by 440 IU (IQR 240–705) at the second visit. 
The iliopsoas (n=8), rectus abdominis (n=7) and quadriceps 
muscle (n=6) were most frequently injected. In the placebo group 
patients were treated with a volume of sterile saline equivalent 
to a median dose of 280 IU (IQR 130–400) at the first visit, and 
450 IU (IQR 240–640) at the second visit; the rectus abdominis 
(n=5) and iliopsoas muscle (n=5) were most frequently injected. 
Usually two muscles per subject were injected (range 1–6). For 
an extensive overview of the injected muscles and corresponding 
doses see online appendix 2.
The interobserver agreement was substantial for the CGI-I and 
CGI-S (average weighted κ=0.65, SD 0.16), and the PMDRS 
(average ICC=0.76, SD 0.11). At the end of the trial-period 9 
out of 25 (36.0%) patients in the BoNT vs 8 out of 22 (34.8%) 
patients in the placebo arm thought they received BoNT. Three 
(12.0%) patients in the BoNT vs 1 (4.3%) in the placebo arm 
could not answer the question.
Regarding the primary outcome measure; 16 of 25 (64.0%) 
patients in the BoNT arm showed improvement of motor symp-
toms (CGI-I score 1, 2 or 3) compared with 13 of 23 (56.5%) 
in the placebo arm (figure 2). This resulted in a non-significant 
proportional difference of 0.075 (95% CI −0.189 to 0.327; 
p=0.77). Multivariable logistic regression analysis, adjusted for 
the stratification variable (extremity vs axial), also did not reveal 
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Table 1 Baseline characteristics of study population.
bonT n=25 Placebo n=23
Age, year (median; IQR) 50.0 (40.0; 61.5) 54.0 (37.0; 57.0)
Gender, n (%)
  Male 14 (56) 14 (61)
Duration of disease, year (median; IQR) 5.0 (2.1; 13.4) 5.3 (2.2; 9.0)
Fahn and Williams diagnostic criteria, n (%)
  Clinically definite 18 (72.0) 16 (69.6)
  Clinically probable 7 (28.0) 7 (30.4)
Additional phenomenology based on PMDRS, n (%)
  Dystonia 12 (48.0) 10 (43.5)
  Tic 3 (12.0) 2 (8.7)
Distribution of jerks/tremor, n (%)
  Abdomen 12 (48.0) 11 (47.8)
  Extremity 13 (52.0) 12 (52.2)
Education level, n (%)
  Primary school 1 (4.0) 2 (8.7)
  Lower education 4 (16.0) 3 (13.0)
  Medium education/higher school 11 (44.0) 12 (52.2)
  Higher education/university 9 (36.0) 6 (26.1)
  Unemployed 17 (68.0) 13 (56.5)
  Disease-related* 13 (52.0) 11 (47.8)
Clinical neurophysiology, n (%)† 13 (52.0) 14 (60.9)
  Pre-movement potential 11 (61.5) 11 (57.1)
Previous treatment, n (%)‡ 21 (84.0) 22 (95.7)
  Rehabilitation 4 (16.0) 5 (21.7)
  Physiotherapy 8 (34.8) 9 (36.0)
  Psychotherapy 5 (20.0) 7 (30.4)
  Other§ 17 (68.0) 17 (73.9)
*Other forms of financial income included retirement (n=4 BoNT vs n=1 placebo), study (n=1 placebo).
†EEG-EMG with backaveraging could not be performed in the whole population.
‡More than one category could apply per patient.
§Other treatment includes acupuncture, homeopathic treatment, alternative medicine, hypnosis, 
benzodiazepines, Selective Serotonin Reuptake Inhibitors (SSRIs), anti-epileptics, dopamine-agonists.
BoNT, botulinum neurotoxin; EEG, electroencephalogram; EMG, electromyogram; PMDRS, Psychogenic 
Movement Disorder Rating Scale.
Figure 2 Distribution of scores of the primary outcome (clinical Global Impression-Improvement scale). The thick black line indicates the cut-off point of 
improvement (score 1, 2 or 3) vs no change or worsening (score 4, 5, 6 and 7). No significant difference was found between the two treatment arms (BoNT 
vs placebo; proportional difference of 0.075 (95% cI −0.189 to 0.327; p=0.77)). BoNT, botulinum neurotoxin.
The CGI-I rated by patients (secondary endpoint), showed a 
perceived improvement (score 1, 2 or 3) in 12 out of 25 (48.0%) 
patients of the BoNT arm compared with 12 out of 23 (52.2%) 
in the placebo arm resulting in a non-significant proportional 
difference of −0.042 (95% CI −0.300 to 0.225; p=1.00). The 
other secondary outcome measures are summarised in table 2. 
There were marginal and non-significant median differences in 
change scores between the BoNT and placebo group.
The post-hoc analysis using a higher cut-off point for 
improvement on the CGI-I (score 1–2 vs 3–7) did not alter our 
results (p=0.349). Also, no significant predictors for treatment 
response were found.
Open-label phase
After completing the trial, 44 of 48 patients participated in the 
open-label phase. Twenty-seven (61.4%) of 44 patients completed 
four treatment sessions in the open-label study (figure 1).
The median dose administered per visit was 350 IU (IQR 
200–480). Usually, two muscles were injected (ranging from 1 to 
8). Due to a mistake made by the pharmacy, one patient received 
placebo instead of BoNT during the first session of the open-
label extension study. He was called back and treated again.
Two (4.5 %) patients were treated once, 9 (20.5%) patients 
twice and 6 (13.6%) patients were treated three times. In the 
final analysis one patient, who refused to cooperate was lost to 
follow-up.
Improvement (score 1, 2 or 3) of motor symptoms on the 
CGI-I assessed by the investigators occurred in 19 of 43 patients 
(44.2%) compared with the end of the randomised trial (see 
figure 3), resulting in a total of 35 out of 43 patients (81.4%) 
showing improvement compared with baseline.
The CGI-I assessed by the patient revealed a perceived motor 
improvement in 24 of 43 patients (55.8%) compared with 
the end of the randomised trial (see figure 3), and in 29 of 43 
patients (67.4%) compared with baseline (for detailed CGI-I 
scores see online appendix 2). The other outcome measures are 
summarised in table 3.
Of the 44 patients who received open-label treatment, 17 
(38.6%) continued treatment with BoNT after the study had 
ended. These were all patients with relapse of symptoms at the 
end of every 3 months. In 6 (13.6%) out of 44 patients symp-
toms diminished/resolved and no further treatment was needed. 
Of the remaining patients, 15 (34.1%) did not benefit enough, 
4 (9.1%) experienced too much side effects, 1 (2.3%) had wors-
ening of symptoms and 1 (2.3%) could not continue treatment 
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Table 2 .Secondary outcome measures the end of the trial.
bonT (n=25) Placebo (n=23) Treatment comparison
Median score (IQr) 
at baseline
Median score (IQr) 
end of trial
Median score (IQr) 
change score
Median score (IQr) 
at baseline
Median score (IQr) 
end of trial
Median score (IQr) 
change score
Median difference 
in change scores 
(95% CI)
P value*
CGI-Severity investigator 3.0 (2.0; 5.0) 3.0 (2.0; 4.0) - 1.0 (−1.0; 0.5) 4.0 (3.0; 5.0) 4.0 (2.0; 5.0) 0.0 (−1.0; 0.0) −1.0 (−1.0 to 1.0) 0.821
CGI-Severity patient 5.0 (4.0; 6.0) 4.0 (3.0; 6.0) 0.0 (−1.5; 1.0) 5.0 (4.0; 6.0) 4.0 (4.0; 5.0) −1.0 (−1.0; 0.0) 1.0 (−1.0 to 1.0) 0.799
VAS-disease burden patient 49.0 (30.5; 71.0) 34.0 (14.0; 78.5) −2.0 (−27.5; 20.0) 62.0 (40.0; 86.0) 48.0 (29.0; 67.0) −2.0 (−48.0; 12.0) 0.0 (−25.0 to 15.0) 0.613
PMDRS-motor symptoms 10.0 (5.0; 18.0) 8.0 (4.5; 15.0) −3.0 (−6.5; 2.5) 17.0 (10.0; 21.0) 16.0 (9.0; 22.0) 0.0 (−5.0; 2.0) −3.0 (−2.0 to 4.0) 0.438




−1.2 (−5.9; 4.4) 33.2 (26.7; 42.1) 32.6 (27.1; 43.0) −1.3 (−3.7; 2.2) 0.1 (−4.2 to 4.2) 0.964




0.2 (−5.6; 3.8) 52.9 (44.0; 60.3) 52.5 (40.0; 60.6) 1.0 (−2.0; 6.4) −0.8 (−3.6 to 5.4) 0.768




0.0 (−2.5; 0.1) 87.4 (79.0; 89.5) 86.9 (79.3; 89.2) −0.3 (−2.1; 0.0) 0.3 (−1.3 to 1.6) 0.624




−1.0 (−4.0; 3.3) 9.0 (5.0; 13.0) 10.0 (3.0; 11.0) 0.0 (−3.0; 1.0) −1.0 (−3.0 to 3.0) 0.802
MADRS-Depressive symptoms 12.0 (5.0; 15.5) 9.0 (4.0; 16.0) 0.0 (−3.0; 3.0) 13.0 (6.0; 18.0) 13.0 (8.0; 22.0) 3.00 (−4.0; 7.0) −3.0 (−1.0 to 6.0) 0.214




1.0 (−1.5; 3.0) 13.0 (8.0; 18.0) 12.0 (5.0; 18.0) 0.0 (−5.0; 2.0) 1.0 (−5.0 to 1.0) 0.213




−2.5 (−6.3; 5.0) 10.0 (3.5; 17.5)
(n=22)







0.0 (−1.0; 3.3) 2.0 (0.0; 5.0) 4.0 (1.0; 7.0) 1.0 (0.0; 3.0) 1.0 (-1.0 to 2.0) 0.300
The missing data should be noticed.
*Mann-Whitney U test.
ALDS, AMC Linear Disability Score; BAI, Beck Anxiety Inventory; BDI, Beck Depression Inventory; CGI, Clinical Global Impression; 95% CI, 95% Confidence Interval (Hodges-Lehmann approach); LSAS, Liebowitz Social 
Anxiety Scale; MADRS, Montgomery Asberg Depression Rating Scale; OCI, Obsessive Compulsive Inventory; PMDRS, Psychogenic Movement Disorder Rating Scale; SF-36, Short Form 36; VAS, Visual Analogue Scale.
Figure 3 Distribution of the clinical Global Impression-Improvement scale scores, assessing improvement of symptoms from the end of trial to the end of 
the open-label study, scored by the investigator and the patient.
Safety
For an overview of all adverse events during the study see 
table 4. During the trial phase equal proportions of patients 
per group had adverse events: BoNT 21/25 (84.0%) vs placebo 
n=20/23 (87.0%). Serious adverse events occurred in two 
patients (n=1 BoNT; ketamine infusion for chronic pain vs n=1 
placebo; hospital admittance for cardial syncope). During the 
open-label phase serious adverse events occurred in five patients 
(lumbar disc herniation surgery (n=1), admittance rehabilitation 
clinic (n=2), ketamine infusion for chronic pain (n=1), surgery 
de Quervain’s disease (n=1)). All serious adverse events were 
deemed not related to the study intervention and reported to the 
local medical ethics committee.
This study provides class I evidence that BoNT treatment in 
jerky and tremulous FMD is not effective compared with placebo.
discussion
In this 4-month randomised placebo-controlled double-blinded 
clinical trial, the effect of BoNT treatment on jerky and tremu-
lous FMD was evaluated. Overall, BoNT was safe and well toler-
ated. We could not demonstrate benefit of BoNT over placebo 
injections in terms of symptom improvement and severity, disease 
burden, quality of life, disability and psychiatric symptoms. At 
the end of the trial phase, motor symptoms of approximately 
60% of patients across both treatment conditions improved; 
44% of patients showed additional improvement at the end of 
the 1-year open-label study compared with the end of the trial. 
Eventually, 81% of patients improved compared with baseline.
Although we assumed the placebo effect to be larger than in a 
similar trial in writer’s cramp,13 we didn’t anticipate the placebo 
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Table 3 Motor symptoms, disease burden, quality of life, disability 
and psychiatric outcome at the end of the open-label follow-up
Median score 
(IQr) at start 
open-label phase
Median score 
(IQr) end of 
follow-up P value*
CGI-severity investigator 3.0 (2.0; 4.0) 2.0 (1.0; 4.0) 0.005
CGI-severity patient 4.0 (4.0; 5.75) 4.0 (2.0; 5.0) 0.044
VAS-disease burden patient 48.0 (20.3; 71.8) 28.0 (3.0; 62.0) 0.042
PMDRS-motor symptoms 10.0 (5.0; 21.0) 9.0 (3.0; 17.0) 0.010
SF-36-Physical component† 34.4 (25.1; 48.3) 40.2 (27.4; 53.6) 0.058
SF-36-Mental component† 52.5 (41.2; 56.9) 50.0 (37.9; 55.7) 0.751
ALDS-disability† 87.8 (79.2; 89.5) 89.1 (83.5; 89.5) 0.790
BDI-Depressive symptoms† 9.0 (4.0; 12.0) 6.0 (3.0; 13.5) 0.370
MADRS-Depressive symptoms 12.0 (15.0; 18.8) 10.0 (4.0; 18.0) 0.205
BAI-Anxiety symptoms† 11.0 (3.5; 17.0) 7.0 (4.0; 16.0) 0.127
LSAS-Social anxiety† 10.0 (4.0; 21.5) 10.0 (2.0; 16.5) 0.446
OCI-Obsessive-Compulsive 
symptoms†
4.0 (1.0; 7.0) 3.0 (1.5; 5.0) 0.028
Bold figures indicate P values< 0.05.
*Wilcoxon signed-rank test for paired data.
†Data of n=41 patients.
ALDS, AMC Linear Disability Score; BAI, Beck Anxiety Inventory; BDI, Beck 
Depression Inventory; CGI, Clinical Global Impression; IQR, Interquartile range; 
LSAS, Liebowitz Social Anxiety Scale; MADRS, Montgomery Asberg Depression 
Rating Scale; OCI, Obsessive Compulsive Inventory; PMDRS, Psychogenic Movement 
Disorder Rating Scale; SF-36, Short Form 36; VAS, Visual Analogue Scale.
Table 4 Number of patients with adverse events; patients could fulfil 








Pain injection site, n (%) 9 (36.0) 2 (8.7) 9 (20.9)
Haematoma injection site, n (%) 2 (8.0) 2 (8.7) 2 (4.7)
Influenza-like symptoms, n (%) 2 (8.0) 4 (17.4) 4 (9.3)
Muscle weakness, n (%) 6 (24.0) 4 (17.4) 12 (27.9)
MRC scale, median (IQR) 5 (5; 5) 5 (5; 5) 5 (5; 5)
Worsening symptoms, n (%) 5 (20.0) 3 (13.0) 3 (7.0)
Other*, n (%) 9 (36.0) 10 (43.5) 19 (44.2)
*Other adverse events included musculoskeletal pain, planned surgery/medical 
intervention, muscle cramps, infection/inflammation, nausea, stomach ache, 
diarrhoea, chest pain, shortness of breath, dizziness, memory problems, transient 
confusion, globus feeling, skin abnormalities, headache and fatigue.
BoNT, botulinum neurotoxin.
symptoms and have had several other treatments before. Other 
randomised treatment studies in FNS are scarce and concern 
physiotherapy,20 rehabilitation,21 disease education,22 23 psycho-
therapy24 and transcranial magnetic stimulation (TMS).25 Most 
are not placebo-controlled and the majority reveals significant 
and clinically relevant improvement in a large proportion of 
patients (30%–70%). One study with a placebo-like control 
condition25 (TMS vs spinal cord stimulation) found large effect 
sizes (66%) in both the intervention and control arm, which is 
in line with our findings. This suggests treatment effects in FNS 
are largely due to placebo-effects and the ‘rituals’ accompanying 
receiving any treatment.26 27 The more invasive, the more effec-
tive a placebo therapy may be.28Although it was not the purview 
of this study, comparing BoNT and placebo to a less invasive 
therapy (eg, massage, explanation) could have given more 
insight in this matter.
The lack of effect of BoNT compared with placebo in jerky and 
tremulous FMD cannot be generalised to other forms of FMD. 
Organic dystonia is the movement disorder most commonly 
treated with BoNT. We chose jerky and tremulous FMD because 
these are more common than functional dystonia1 2 and the diag-
nostic process can be aided by neurophysiologic tests.4 Effective 
treatment of functional (fixed) dystonia in a small group with 
subclinical amounts of BoNT has been described.11 The immediate 
improvement after injections in this study suggests a placebo-effect. 
Further, a recent small trial (n=10) in functional dystonia showed 
no benefit of BoNT over placebo prior to cognitive behavioural 
therapy.29 In general, it is still debated whether the treatment of 
FNS should be equalised or specialised to specific motor pheno-
types.30 Based on our study and the literature definite conclusions 
cannot be drawn but BoNT and placebo appears to be as effective 
in both jerky/tremulous as dystonic FMD.
Apart from the large placebo response, an additional effect of 
BoNT cannot be excluded. In the open-label extension phase a 
large proportion of patients still improved compared with the 
blinded phase. Future dose and treatment duration-finding studies 
using larger study groups may help to pick up smaller effects. 
However, given the results of our study it seems more relevant to 
focus on placebo-like therapies.
Our study population included chronically ill patients (median 
symptom duration of 5 years) in whom, according to the litera-
ture, prognosis is often poor (on average 39% of patients display 
persistent or worsening symptoms).5 The proportion of patients 
which improved is therefore a remarkable finding. Notably, this 
did not translate into amelioration of disability, quality of life 
and psychiatric symptoms. Unfortunately we could not identify 
any traits (eg, pain or fatigue) of treatment-responders or non-re-
sponders in our post-hoc analyses, which should be interpreted 
with caution given the small study population. Ultimately, a 
substantial part of patients (n=17) chose to continue BoNT treat-
ment after the study, suggesting that patients did perceive benefit 
of the treatment.
The amount of patients included was the result screening of 
a large number of eligible patients (48 (20%) of 239 patients 
screened). This is in line with other studies of FNS,20 22 23 but ques-
tions the generalisability of the results to all jerky and tremulous 
FMD patients. However, of the 109 excluded patients the reason 
was clinically relevant as in almost half of them symptoms dimin-
ished severely or resolved, in about a quarter the symptoms were 
not amendable for injections, and of the remaining quarter there 
were other reasons including a non-functional disorder. Another 
interesting observation in our population was the equal number 
of men and women, not only in the study population, but also 
in the large screening pool. Axial jerks do tend to occur more 
often in men,6 so this might be an explanation of our popula-
tion not reflecting the usual demographics of FMD with a female 
predominance.
lIMITATIOns
Limitations of this study include the small study population and 
the large number of eligible patients which had to be screened in 
order to reach the required amount of patients. Also, the patient 
who was analysed after 1 year instead of 4 months was a major 
protocol violation.
COnClusIOns
In this RCT of BoNT for jerky and tremulous FMD, we found 
no evidence of improved outcomes in patients treated with BoNT 
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very large. Our study underlines the potential of patients with 
chronic FMD to improve. Despite the possible ethical issues, we 
advocate further exploration of placebo-like therapies in FMD.
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